Bausch + Lomb Launches PreserVision AREDS3 Eye Vitamins
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 19 2026
0mins
Bausch + Lomb announced the U.S. launch of PreserVision AREDS3 eye vitamins, which combine the clinically proven AREDS2 nutrients recommended by the NEI to help reduce the risk of moderate-to-advanced AMD progression with a unique B-vitamin complex. "AMD affects millions of people, often long before symptoms meaningfully change day-to-day life," said John Ferris, president, Consumer, Bausch + Lomb. "Historically, options to support macular health earlier in the condition have been limited. PreserVision AREDS3 reflects decades of research, and our commitment to advancing eye health through science, offering an option for a broader range of people looking to support their macular health."*
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BLCO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BLCO
Wall Street analysts forecast BLCO stock price to rise
10 Analyst Rating
4 Buy
5 Hold
1 Sell
Moderate Buy
Current: 15.590
Low
13.00
Averages
18.11
High
21.00
Current: 15.590
Low
13.00
Averages
18.11
High
21.00
About BLCO
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Bausch + Lomb Announces 2026 Annual Meeting Director Elections Results
- Director Election Results: At the 2026 Annual Meeting, Bausch + Lomb elected 10 directors, with Eduardo Alfonso, M.D. receiving 331,573,622 votes in favor and 4,244,069 against, indicating strong shareholder confidence in his leadership.
- Executive Compensation Approval: Shareholders approved the compensation of named executive officers in a non-binding advisory vote, reflecting recognition of the management team and potentially enhancing executive motivation and retention.
- Auditor Appointment: The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm until the 2027 Annual Meeting ensures financial transparency and compliance for the company.
- Commitment to Disclosure: The company will file a report with the U.S. Securities and Exchange Commission detailing the final vote results and will make this report available on its website, demonstrating a commitment to transparency and shareholder communication.
See More
Bausch + Lomb Q1 2026 Earnings Call Insights
- Stable Revenue Growth: Bausch + Lomb reported Q1 revenue of $1.244 billion, reflecting a 6% year-over-year growth, with foreign exchange contributing approximately $42 million, indicating the company's stability and enhanced profitability in the market.
- Surgical Business Challenges: Although the surgical segment showed growth, results fell short of expectations due to weather-related disruptions and reimbursement pressures, with the CEO emphasizing the need to rebuild the U.S. surgical team to strengthen competitive positioning.
- Improved Adjusted EPS: The adjusted EPS for the quarter was $0.08, compared to a loss of $0.07 in the prior year, reflecting improvements in the quality of earnings and effective conversion of operating leverage.
- Full-Year Revenue Guidance Raised: The company raised its full-year revenue guidance by $45 million to a range of $5.42 billion to $5.52 billion, demonstrating management's confidence in future performance despite external cost pressures.
See More
Bausch + Lomb Q1 Earnings Beat Expectations with Revenue Growth
- Strong Earnings Report: Bausch + Lomb reported a Q1 non-GAAP EPS of $0.05, aligning with expectations, indicating stability in the company's profitability.
- Revenue Growth: The company achieved revenue of $1.24 billion, an 8.8% year-over-year increase, beating market expectations by $20 million, reflecting robust recovery in product demand.
- Adjusted EBITDA Performance: Adjusted EBITDA stood at $189 million, with $200 million excluding acquired IPR&D, demonstrating ongoing improvements in cost control and operational efficiency.
- 2026 Outlook: Bausch + Lomb raised its revenue and adjusted EBITDA guidance for 2026, targeting $5.475 billion, showcasing confidence in growth from the dry eye market and the strategic potential of its expansion plans.
See More
Bausch + Lomb Launches Bi-Blade+ Retina Cutter with Enhanced Features
- Increased Cutting Speed: The Bi-Blade+ features a cutting speed of 25,000 cuts per minute, significantly minimizing retinal traction and enhancing vitreous flow, which boosts surgical efficiency and surgeon confidence.
- Flow Rate Efficiency: Compared to the Bi-Blade, the Bi-Blade+ achieves a 25% increase in average flow rate, making vitreous removal more efficient and optimizing surgical outcomes.
- Reduced Pressure Fluctuations: When used with Adaptive Fluidics, Bi-Blade+ demonstrates a 62% reduction in average infusion pressure during surgery, ensuring intraocular pressure stability and reducing surgical risks.
- Clinical Application Prospects: A study showed that the combination of Bi-Blade+ and Adaptive Fluidics significantly improved intraocular pressure, bringing it closer to physiological levels (10-20 mmHg), thus providing a better operational experience for retinal surgeries.
See More
Bausch + Lomb to Release Q1 Financial Results on April 29, 2026
- Earnings Release Schedule: Bausch + Lomb will announce its Q1 financial results on April 29, 2026, and host a conference call and live webcast at 8 a.m. ET to provide investors with the latest business updates.
- Investor Relations Materials: All relevant materials will be made available on the Investor Relations section of Bausch + Lomb's website prior to the call, ensuring investors have timely access to key information for informed decision-making.
- Conference Call Details: Participants can join the call by dialing +1 (888) 506-0062 for North America or +1 (973) 528-0011 for international access, using access code 666753 to ensure smooth entry into the call.
- Replay Information: The call will be available for replay via +1 (877) 481-4010 for North America and +1 (919) 882-2331 for international callers, with the replay accessible until May 13, 2026, allowing investors who missed the live event to catch up on the discussion.
See More
Bausch + Lomb Director Acquires 4,300 Shares Amid Ownership Strategy
- Director Share Acquisition: Bausch + Lomb's Director Alfonso Eduardo purchased 4,300 common shares for approximately $77,000, reflecting his confidence in the company's future while progressing towards a mandatory $400,000 equity ownership requirement.
- Matching Share Program: This purchase triggered the company's matching share program, granting Eduardo an additional 4,300 restricted share units that will vest in thirds over three years, indicating his commitment to the company's long-term growth.
- Market Price Analysis: Eduardo acquired shares at $17.90 each, slightly below the March 2 closing price of $18.41, suggesting a strategic move to invest while meeting the director ownership requirement amidst market fluctuations.
- Investor Considerations: This transaction illustrates a new director effectively building his stake through the matching program; although Eduardo invested real cash, the vesting restrictions on the shares require him to remain on the board for three years, which is a positive governance signal for retail investors.
See More
Bausch + Lomb Announces 2026 Annual Meeting Director Elections Results
- Director Election Results: At the 2026 Annual Meeting, Bausch + Lomb elected 10 directors, with Eduardo Alfonso, M.D. receiving 331,573,622 votes in favor and 4,244,069 against, indicating strong shareholder confidence in his leadership.
- Executive Compensation Approval: Shareholders approved the compensation of named executive officers in a non-binding advisory vote, reflecting recognition of the management team and potentially enhancing executive motivation and retention.
- Auditor Appointment: The appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm until the 2027 Annual Meeting ensures financial transparency and compliance for the company.
- Commitment to Disclosure: The company will file a report with the U.S. Securities and Exchange Commission detailing the final vote results and will make this report available on its website, demonstrating a commitment to transparency and shareholder communication.
See More
Bausch + Lomb Q1 2026 Earnings Call Insights
- Stable Revenue Growth: Bausch + Lomb reported Q1 revenue of $1.244 billion, reflecting a 6% year-over-year growth, with foreign exchange contributing approximately $42 million, indicating the company's stability and enhanced profitability in the market.
- Surgical Business Challenges: Although the surgical segment showed growth, results fell short of expectations due to weather-related disruptions and reimbursement pressures, with the CEO emphasizing the need to rebuild the U.S. surgical team to strengthen competitive positioning.
- Improved Adjusted EPS: The adjusted EPS for the quarter was $0.08, compared to a loss of $0.07 in the prior year, reflecting improvements in the quality of earnings and effective conversion of operating leverage.
- Full-Year Revenue Guidance Raised: The company raised its full-year revenue guidance by $45 million to a range of $5.42 billion to $5.52 billion, demonstrating management's confidence in future performance despite external cost pressures.
See More
Bausch + Lomb Q1 Earnings Beat Expectations with Revenue Growth
- Strong Earnings Report: Bausch + Lomb reported a Q1 non-GAAP EPS of $0.05, aligning with expectations, indicating stability in the company's profitability.
- Revenue Growth: The company achieved revenue of $1.24 billion, an 8.8% year-over-year increase, beating market expectations by $20 million, reflecting robust recovery in product demand.
- Adjusted EBITDA Performance: Adjusted EBITDA stood at $189 million, with $200 million excluding acquired IPR&D, demonstrating ongoing improvements in cost control and operational efficiency.
- 2026 Outlook: Bausch + Lomb raised its revenue and adjusted EBITDA guidance for 2026, targeting $5.475 billion, showcasing confidence in growth from the dry eye market and the strategic potential of its expansion plans.
See More
Bausch + Lomb Launches Bi-Blade+ Retina Cutter with Enhanced Features
- Increased Cutting Speed: The Bi-Blade+ features a cutting speed of 25,000 cuts per minute, significantly minimizing retinal traction and enhancing vitreous flow, which boosts surgical efficiency and surgeon confidence.
- Flow Rate Efficiency: Compared to the Bi-Blade, the Bi-Blade+ achieves a 25% increase in average flow rate, making vitreous removal more efficient and optimizing surgical outcomes.
- Reduced Pressure Fluctuations: When used with Adaptive Fluidics, Bi-Blade+ demonstrates a 62% reduction in average infusion pressure during surgery, ensuring intraocular pressure stability and reducing surgical risks.
- Clinical Application Prospects: A study showed that the combination of Bi-Blade+ and Adaptive Fluidics significantly improved intraocular pressure, bringing it closer to physiological levels (10-20 mmHg), thus providing a better operational experience for retinal surgeries.
See More
Bausch + Lomb to Release Q1 Financial Results on April 29, 2026
- Earnings Release Schedule: Bausch + Lomb will announce its Q1 financial results on April 29, 2026, and host a conference call and live webcast at 8 a.m. ET to provide investors with the latest business updates.
- Investor Relations Materials: All relevant materials will be made available on the Investor Relations section of Bausch + Lomb's website prior to the call, ensuring investors have timely access to key information for informed decision-making.
- Conference Call Details: Participants can join the call by dialing +1 (888) 506-0062 for North America or +1 (973) 528-0011 for international access, using access code 666753 to ensure smooth entry into the call.
- Replay Information: The call will be available for replay via +1 (877) 481-4010 for North America and +1 (919) 882-2331 for international callers, with the replay accessible until May 13, 2026, allowing investors who missed the live event to catch up on the discussion.
See More
Bausch + Lomb Director Acquires 4,300 Shares Amid Ownership Strategy
- Director Share Acquisition: Bausch + Lomb's Director Alfonso Eduardo purchased 4,300 common shares for approximately $77,000, reflecting his confidence in the company's future while progressing towards a mandatory $400,000 equity ownership requirement.
- Matching Share Program: This purchase triggered the company's matching share program, granting Eduardo an additional 4,300 restricted share units that will vest in thirds over three years, indicating his commitment to the company's long-term growth.
- Market Price Analysis: Eduardo acquired shares at $17.90 each, slightly below the March 2 closing price of $18.41, suggesting a strategic move to invest while meeting the director ownership requirement amidst market fluctuations.
- Investor Considerations: This transaction illustrates a new director effectively building his stake through the matching program; although Eduardo invested real cash, the vesting restrictions on the shares require him to remain on the board for three years, which is a positive governance signal for retail investors.
See More
